Danaher (NYSE:DHR) Releases Quarterly Earnings Results, Beats Expectations By $0.15 EPS

Danaher (NYSE:DHR) posted its earnings results on Tuesday. The conglomerate reported $1.72 EPS for the quarter, topping the consensus estimate of $1.57 by $0.15, Briefing.com reports. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same period last year, the company posted $2.05 EPS. The company’s quarterly revenue was down 2.9% compared to the same quarter last year.

Danaher Stock Performance

NYSE DHR traded up $3.84 during trading hours on Friday, hitting $273.93. 865,776 shares of the company’s stock traded hands, compared to its average volume of 2,908,438. The business’s fifty day moving average price is $254.99 and its two-hundred day moving average price is $248.82. The company has a current ratio of 1.43, a quick ratio of 1.51 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $197.83 billion, a P/E ratio of 45.78, a P/E/G ratio of 4.11 and a beta of 0.83. Danaher has a 52 week low of $182.09 and a 52 week high of $277.72.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be given a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, June 28th. This represents a $1.08 annualized dividend and a yield of 0.39%. Danaher’s dividend payout ratio (DPR) is 18.31%.

Insider Activity at Danaher

In other Danaher news, Director Alan G. Spoon sold 708 shares of Danaher stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total transaction of $172,454.64. Following the transaction, the director now owns 116,202 shares of the company’s stock, valued at $28,304,483.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CFO Matthew Mcgrew sold 46,377 shares of the business’s stock in a transaction on Friday, May 10th. The shares were sold at an average price of $253.05, for a total value of $11,735,699.85. Following the transaction, the chief financial officer now owns 29,407 shares of the company’s stock, valued at $7,441,441.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Alan G. Spoon sold 708 shares of the business’s stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total transaction of $172,454.64. Following the completion of the transaction, the director now directly owns 116,202 shares in the company, valued at approximately $28,304,483.16. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 75,175 shares of company stock worth $19,161,154. 11.10% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Robert W. Baird raised their target price on shares of Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a research report on Wednesday. Citigroup lifted their price target on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Royal Bank of Canada lifted their price target on shares of Danaher from $297.00 to $300.00 and gave the company an “outperform” rating in a research report on Wednesday. Finally, Jefferies Financial Group initiated coverage on shares of Danaher in a research report on Monday, June 3rd. They set a “buy” rating and a $295.00 price target for the company. Six research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat.com, Danaher has a consensus rating of “Moderate Buy” and an average price target of $276.88.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.